Analyst Price Targets — EVMN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 30, 2026 10:55 am | — | Morgan Stanley | $26.00 | $15.05 | TheFly | Evommune price target lowered to $26 from $55 at Morgan Stanley |
| May 26, 2026 10:54 am | Mitchell Kapoor | H.C. Wainwright | $50.00 | $22.87 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Evommune Inc (EVMN) |
| May 11, 2026 12:16 pm | — | Morgan Stanley | $55.00 | $24.50 | TheFly | Evommune price target raised to $55 from $54 at Morgan Stanley |
| February 18, 2026 6:16 pm | Judah Frommer | Morgan Stanley | $54.00 | $31.06 | TheFly | Evommune price target raised to $54 from $36 at Morgan Stanley |
| February 10, 2026 6:28 pm | — | Evercore ISI | $55.00 | $30.10 | TheFly | Evommune price target raised to $55 from $40 at Evercore ISI |
| February 10, 2026 5:53 pm | Mitchell Kapoor | H.C. Wainwright | $65.00 | $28.81 | TheFly | Evommune price target raised to $65 from $35 at H.C. Wainwright |
| January 22, 2026 1:12 pm | — | Oppenheimer | $42.00 | $18.48 | TheFly | Evommune initiated with an Outperform at Oppenheimer |
| January 7, 2026 9:34 pm | — | Raymond James | $40.00 | $16.20 | TheFly | Evommune initiated with a Strong Buy at Raymond James |
| January 6, 2026 11:10 am | Mitchell Kapoor | H.C. Wainwright | $35.00 | $15.37 | TheFly | Evommune initiated with a Buy at H.C. Wainwright |
| December 1, 2025 12:43 pm | Thomas Smith | Leerink Partners | $42.00 | $20.71 | TheFly | Evommune initiated with an Outperform at Leerink |
Latest News for EVMN
Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session. NEW YORK, July 7, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shareholders lost approximately 38% of their investment value on June 29, 2026, when the Company disclosed that its lead drug candidate EVO756 failed to meet the…
Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD and migraine. However, remember that EVO301 still gives EVMN another catalyst after their positive Phase 2a AD data.
Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier -- days before the Company disclosed that EVO756 failed its Phase 2b primary endpoint. NEW YORK, June 30, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shares dropped approximately 38% after the Company announced that its lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial evaluating…
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for EVMN.
Senate Trading
No Senate trades found for EVMN.
U.S. House Trading
No House trades found for EVMN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.